{"id":"https://openalex.org/W7225319139","doi":"https://doi.org/10.1007/s00280-026-04969-8","title":"A phase 1 study of 4\u2019-thio-2\u2019-deoxycytidine in patients with solid tumors","display_name":"A phase 1 study of 4\u2019-thio-2\u2019-deoxycytidine in patients with solid tumors","publication_year":2026,"publication_date":"2026-11-05","ids":{"openalex":"https://openalex.org/W7225319139","doi":"https://doi.org/10.1007/s00280-026-04969-8","pmid":"https://pubmed.ncbi.nlm.nih.gov/42986444","pmcid":"https://www.ncbi.nlm.nih.gov/pmc/articles/13739968"},"language":"en","primary_location":{"id":"doi:10.1007/s00280-026-04969-8","doi":"https://doi.org/10.1007/s00280-026-04969-8","is_oa":true,"landing_page_url":"https://doi.org/10.1007/s00280-026-04969-8","pdf_url":"https://link.springer.com/content/pdf/10.1007/s00280-026-04969-8.pdf","source":{"id":"https://openalex.org/S117498271","display_name":"Cancer Chemotherapy and Pharmacology","issn_l":"0344-5704","issn":["0344-5704","1432-0843"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["cwts-core","dongbi-b","doyens","jufo-1","ki-jl-1","medline","norway-1","poland-100","russia-white-list-1"],"host_organization":"https://openalex.org/P4310319900","host_organization_name":"Springer Science+Business Media","host_organization_lineage":["https://openalex.org/P4310319900","https://openalex.org/P4310319965"],"host_organization_lineage_names":["Springer Science+Business Media","Springer Nature"],"type":"journal"},"license":"cc-by","license_id":"https://openalex.org/licenses/cc-by","version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Cancer Chemotherapy and Pharmacology","raw_type":"journal-article"},"volume":null,"type":"article","is_traditional":true,"indexed_in":["crossref","pubmed"],"open_access":{"is_oa":true,"oa_status":"hybrid","oa_url":"https://link.springer.com/content/pdf/10.1007/s00280-026-04969-8.pdf","any_repository_has_fulltext":true},"authorships":[{"author_position":"first","author":{"id":"https://openalex.org/A5017244775","display_name":"Geraldine O\u2019Sullivan Coyne","orcid":"https://orcid.org/0000-0002-2918-6326","observed_orcids":["https://orcid.org/0000-0002-2918-6326"]},"institutions":[{"id":"https://openalex.org/I1299303238","display_name":"National Institutes of Health","ror":"https://ror.org/01cwqze88","country_code":"US","type":"government","lineage":["https://openalex.org/I1299022934","https://openalex.org/I1299303238"]},{"id":"https://openalex.org/I1302444339","display_name":"Northwell Health","ror":"https://ror.org/02bxt4m23","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I1302444339"]},{"id":"https://openalex.org/I4210140884","display_name":"National Cancer Institute","ror":"https://ror.org/040gcmg81","country_code":"US","type":"government","lineage":["https://openalex.org/I1299022934","https://openalex.org/I1299303238","https://openalex.org/I4210140884"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Geraldine O\u2019Sullivan Coyne","raw_affiliation_strings":["Division of Cancer Treatment and Diagnosis, National Cancer Institute, NIH, 31 Center Drive, Bldg. 31 Room 3A-44, Bethesda, 20892, MD, USA","START Center for Cancer Research, Northwell Health Cancer Institute, NY, USA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Division of Cancer Treatment and Diagnosis, National Cancer Institute, NIH, 31 Center Drive, Bldg. 31 Room 3A-44, Bethesda, 20892, MD, USA","institution_ids":["https://openalex.org/I1299303238","https://openalex.org/I4210140884"]},{"raw_affiliation_string":"START Center for Cancer Research, Northwell Health Cancer Institute, NY, USA","institution_ids":["https://openalex.org/I1302444339"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5003847273","display_name":"Shivaani Kummar","orcid":"https://orcid.org/0000-0001-6906-1627","observed_orcids":["https://orcid.org/0000-0001-6906-1627"]},"institutions":[{"id":"https://openalex.org/I1299303238","display_name":"National Institutes of Health","ror":"https://ror.org/01cwqze88","country_code":"US","type":"government","lineage":["https://openalex.org/I1299022934","https://openalex.org/I1299303238"]},{"id":"https://openalex.org/I4210140884","display_name":"National Cancer Institute","ror":"https://ror.org/040gcmg81","country_code":"US","type":"government","lineage":["https://openalex.org/I1299022934","https://openalex.org/I1299303238","https://openalex.org/I4210140884"]},{"id":"https://openalex.org/I4390039369","display_name":"OHSU Knight Cancer Institute","ror":"https://ror.org/002shna07","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I165690674","https://openalex.org/I4390039369"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Shivaani Kummar","raw_affiliation_strings":["Division of Cancer Treatment and Diagnosis, National Cancer Institute, NIH, 31 Center Drive, Bldg. 31 Room 3A-44, Bethesda, 20892, MD, USA","Knight Cancer Institute, Oregon Health and Science University, Portland, OR, USA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Division of Cancer Treatment and Diagnosis, National Cancer Institute, NIH, 31 Center Drive, Bldg. 31 Room 3A-44, Bethesda, 20892, MD, USA","institution_ids":["https://openalex.org/I1299303238","https://openalex.org/I4210140884"]},{"raw_affiliation_string":"Knight Cancer Institute, Oregon Health and Science University, Portland, OR, USA","institution_ids":["https://openalex.org/I4390039369"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5160857348","display_name":"Larry Rubinstein","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I1299303238","display_name":"National Institutes of Health","ror":"https://ror.org/01cwqze88","country_code":"US","type":"government","lineage":["https://openalex.org/I1299022934","https://openalex.org/I1299303238"]},{"id":"https://openalex.org/I4210140884","display_name":"National Cancer Institute","ror":"https://ror.org/040gcmg81","country_code":"US","type":"government","lineage":["https://openalex.org/I1299022934","https://openalex.org/I1299303238","https://openalex.org/I4210140884"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Larry Rubinstein","raw_affiliation_strings":["Division of Cancer Treatment and Diagnosis, National Cancer Institute, NIH, 31 Center Drive, Bldg. 31 Room 3A-44, Bethesda, 20892, MD, USA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Division of Cancer Treatment and Diagnosis, National Cancer Institute, NIH, 31 Center Drive, Bldg. 31 Room 3A-44, Bethesda, 20892, MD, USA","institution_ids":["https://openalex.org/I1299303238","https://openalex.org/I4210140884"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5067404225","display_name":"Larry D. Anderson Jr.","orcid":"https://orcid.org/0009-0002-2211-3420","observed_orcids":["https://orcid.org/0009-0002-2211-3420"]},"institutions":[{"id":"https://openalex.org/I1299303238","display_name":"National Institutes of Health","ror":"https://ror.org/01cwqze88","country_code":"US","type":"government","lineage":["https://openalex.org/I1299022934","https://openalex.org/I1299303238"]},{"id":"https://openalex.org/I4210140884","display_name":"National Cancer Institute","ror":"https://ror.org/040gcmg81","country_code":"US","type":"government","lineage":["https://openalex.org/I1299022934","https://openalex.org/I1299303238","https://openalex.org/I4210140884"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Larry Anderson","raw_affiliation_strings":["Division of Cancer Treatment and Diagnosis, National Cancer Institute, NIH, 31 Center Drive, Bldg. 31 Room 3A-44, Bethesda, 20892, MD, USA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Division of Cancer Treatment and Diagnosis, National Cancer Institute, NIH, 31 Center Drive, Bldg. 31 Room 3A-44, Bethesda, 20892, MD, USA","institution_ids":["https://openalex.org/I1299303238","https://openalex.org/I4210140884"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5033250934","display_name":"Kimberly D. Hill","orcid":"https://orcid.org/0000-0001-9120-9288","observed_orcids":["https://orcid.org/0000-0001-9120-9288"]},"institutions":[{"id":"https://openalex.org/I1299303238","display_name":"National Institutes of Health","ror":"https://ror.org/01cwqze88","country_code":"US","type":"government","lineage":["https://openalex.org/I1299022934","https://openalex.org/I1299303238"]},{"id":"https://openalex.org/I4210140884","display_name":"National Cancer Institute","ror":"https://ror.org/040gcmg81","country_code":"US","type":"government","lineage":["https://openalex.org/I1299022934","https://openalex.org/I1299303238","https://openalex.org/I4210140884"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Kimberly Hill","raw_affiliation_strings":["Division of Cancer Treatment and Diagnosis, National Cancer Institute, NIH, 31 Center Drive, Bldg. 31 Room 3A-44, Bethesda, 20892, MD, USA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Division of Cancer Treatment and Diagnosis, National Cancer Institute, NIH, 31 Center Drive, Bldg. 31 Room 3A-44, Bethesda, 20892, MD, USA","institution_ids":["https://openalex.org/I1299303238","https://openalex.org/I4210140884"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5035279705","display_name":"Ashley B. Bruns","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I1299303238","display_name":"National Institutes of Health","ror":"https://ror.org/01cwqze88","country_code":"US","type":"government","lineage":["https://openalex.org/I1299022934","https://openalex.org/I1299303238"]},{"id":"https://openalex.org/I4210140884","display_name":"National Cancer Institute","ror":"https://ror.org/040gcmg81","country_code":"US","type":"government","lineage":["https://openalex.org/I1299022934","https://openalex.org/I1299303238","https://openalex.org/I4210140884"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Ashley Bruns","raw_affiliation_strings":["Division of Cancer Treatment and Diagnosis, National Cancer Institute, NIH, 31 Center Drive, Bldg. 31 Room 3A-44, Bethesda, 20892, MD, USA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Division of Cancer Treatment and Diagnosis, National Cancer Institute, NIH, 31 Center Drive, Bldg. 31 Room 3A-44, Bethesda, 20892, MD, USA","institution_ids":["https://openalex.org/I1299303238","https://openalex.org/I4210140884"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5113196277","display_name":"Nancy Moore","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I1299303238","display_name":"National Institutes of Health","ror":"https://ror.org/01cwqze88","country_code":"US","type":"government","lineage":["https://openalex.org/I1299022934","https://openalex.org/I1299303238"]},{"id":"https://openalex.org/I4210140884","display_name":"National Cancer Institute","ror":"https://ror.org/040gcmg81","country_code":"US","type":"government","lineage":["https://openalex.org/I1299022934","https://openalex.org/I1299303238","https://openalex.org/I4210140884"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Nancy Moore","raw_affiliation_strings":["Division of Cancer Treatment and Diagnosis, National Cancer Institute, NIH, 31 Center Drive, Bldg. 31 Room 3A-44, Bethesda, 20892, MD, USA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Division of Cancer Treatment and Diagnosis, National Cancer Institute, NIH, 31 Center Drive, Bldg. 31 Room 3A-44, Bethesda, 20892, MD, USA","institution_ids":["https://openalex.org/I1299303238","https://openalex.org/I4210140884"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5009616372","display_name":"Katherine V. Ferry\u2010Galow","orcid":"https://orcid.org/0009-0007-0795-2089","observed_orcids":["https://orcid.org/0009-0007-0795-2089"]},"institutions":[{"id":"https://openalex.org/I4210130649","display_name":"Frederick National Laboratory for Cancer Research","ror":"https://ror.org/03v6m3209","country_code":"US","type":"facility","lineage":["https://openalex.org/I1299022934","https://openalex.org/I1299303238","https://openalex.org/I4210130649","https://openalex.org/I4210140884"]},{"id":"https://openalex.org/I4396570585","display_name":"Leidos Biomedical Research Inc. (United States)","ror":"https://ror.org/00bardy64","country_code":"US","type":"company","lineage":["https://openalex.org/I114662689","https://openalex.org/I4396570585"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Katherine V. Ferry-Galow","raw_affiliation_strings":["Clinical Pharmacodynamic Biomarkers Program, Applied/Developmental Research Directorate, Frederick National Laboratory for Cancer Research, Frederick, MD, USA","Leidos Biomedical Research, Frederick National Laboratory for Cancer Research, Frederick, MD, 21702, USA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Clinical Pharmacodynamic Biomarkers Program, Applied/Developmental Research Directorate, Frederick National Laboratory for Cancer Research, Frederick, MD, USA","institution_ids":["https://openalex.org/I4210130649"]},{"raw_affiliation_string":"Leidos Biomedical Research, Frederick National Laboratory for Cancer Research, Frederick, MD, 21702, USA","institution_ids":["https://openalex.org/I4210130649","https://openalex.org/I4396570585"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5015442703","display_name":"Brandon L. Miller","orcid":"https://orcid.org/0000-0003-1523-9092","observed_orcids":["https://orcid.org/0000-0003-1523-9092"]},"institutions":[{"id":"https://openalex.org/I4210130649","display_name":"Frederick National Laboratory for Cancer Research","ror":"https://ror.org/03v6m3209","country_code":"US","type":"facility","lineage":["https://openalex.org/I1299022934","https://openalex.org/I1299303238","https://openalex.org/I4210130649","https://openalex.org/I4210140884"]},{"id":"https://openalex.org/I4396570585","display_name":"Leidos Biomedical Research Inc. (United States)","ror":"https://ror.org/00bardy64","country_code":"US","type":"company","lineage":["https://openalex.org/I114662689","https://openalex.org/I4396570585"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Brandon Miller","raw_affiliation_strings":["Clinical Pharmacodynamic Biomarkers Program, Applied/Developmental Research Directorate, Frederick National Laboratory for Cancer Research, Frederick, MD, USA","Leidos Biomedical Research, Frederick National Laboratory for Cancer Research, Frederick, MD, 21702, USA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Clinical Pharmacodynamic Biomarkers Program, Applied/Developmental Research Directorate, Frederick National Laboratory for Cancer Research, Frederick, MD, USA","institution_ids":["https://openalex.org/I4210130649"]},{"raw_affiliation_string":"Leidos Biomedical Research, Frederick National Laboratory for Cancer Research, Frederick, MD, 21702, USA","institution_ids":["https://openalex.org/I4210130649","https://openalex.org/I4396570585"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5160898303","display_name":"Lihua Wang","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I4210130649","display_name":"Frederick National Laboratory for Cancer Research","ror":"https://ror.org/03v6m3209","country_code":"US","type":"facility","lineage":["https://openalex.org/I1299022934","https://openalex.org/I1299303238","https://openalex.org/I4210130649","https://openalex.org/I4210140884"]},{"id":"https://openalex.org/I4396570585","display_name":"Leidos Biomedical Research Inc. (United States)","ror":"https://ror.org/00bardy64","country_code":"US","type":"company","lineage":["https://openalex.org/I114662689","https://openalex.org/I4396570585"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Lihua Wang","raw_affiliation_strings":["Clinical Pharmacodynamic Biomarkers Program, Applied/Developmental Research Directorate, Frederick National Laboratory for Cancer Research, Frederick, MD, USA","Leidos Biomedical Research, Frederick National Laboratory for Cancer Research, Frederick, MD, 21702, USA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Clinical Pharmacodynamic Biomarkers Program, Applied/Developmental Research Directorate, Frederick National Laboratory for Cancer Research, Frederick, MD, USA","institution_ids":["https://openalex.org/I4210130649"]},{"raw_affiliation_string":"Leidos Biomedical Research, Frederick National Laboratory for Cancer Research, Frederick, MD, 21702, USA","institution_ids":["https://openalex.org/I4210130649","https://openalex.org/I4396570585"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5034690406","display_name":"Joseph M. Covey","orcid":"https://orcid.org/0000-0002-5696-8999","observed_orcids":["https://orcid.org/0000-0002-5696-8999"]},"institutions":[{"id":"https://openalex.org/I1299303238","display_name":"National Institutes of Health","ror":"https://ror.org/01cwqze88","country_code":"US","type":"government","lineage":["https://openalex.org/I1299022934","https://openalex.org/I1299303238"]},{"id":"https://openalex.org/I4210140884","display_name":"National Cancer Institute","ror":"https://ror.org/040gcmg81","country_code":"US","type":"government","lineage":["https://openalex.org/I1299022934","https://openalex.org/I1299303238","https://openalex.org/I4210140884"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Joseph M. Covey","raw_affiliation_strings":["Division of Cancer Treatment and Diagnosis, National Cancer Institute, NIH, 31 Center Drive, Bldg. 31 Room 3A-44, Bethesda, 20892, MD, USA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Division of Cancer Treatment and Diagnosis, National Cancer Institute, NIH, 31 Center Drive, Bldg. 31 Room 3A-44, Bethesda, 20892, MD, USA","institution_ids":["https://openalex.org/I1299303238","https://openalex.org/I4210140884"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5046042179","display_name":"Richard Piekarz","orcid":"https://orcid.org/0000-0002-3591-7893","observed_orcids":["https://orcid.org/0000-0002-3591-7893"]},"institutions":[{"id":"https://openalex.org/I1299303238","display_name":"National Institutes of Health","ror":"https://ror.org/01cwqze88","country_code":"US","type":"government","lineage":["https://openalex.org/I1299022934","https://openalex.org/I1299303238"]},{"id":"https://openalex.org/I4210140884","display_name":"National Cancer Institute","ror":"https://ror.org/040gcmg81","country_code":"US","type":"government","lineage":["https://openalex.org/I1299022934","https://openalex.org/I1299303238","https://openalex.org/I4210140884"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Richard L. Piekarz","raw_affiliation_strings":["Division of Cancer Treatment and Diagnosis, National Cancer Institute, NIH, 31 Center Drive, Bldg. 31 Room 3A-44, Bethesda, 20892, MD, USA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Division of Cancer Treatment and Diagnosis, National Cancer Institute, NIH, 31 Center Drive, Bldg. 31 Room 3A-44, Bethesda, 20892, MD, USA","institution_ids":["https://openalex.org/I1299303238","https://openalex.org/I4210140884"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5065979640","display_name":"Laura Kuhlmann","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I1299303238","display_name":"National Institutes of Health","ror":"https://ror.org/01cwqze88","country_code":"US","type":"government","lineage":["https://openalex.org/I1299022934","https://openalex.org/I1299303238"]},{"id":"https://openalex.org/I4210140884","display_name":"National Cancer Institute","ror":"https://ror.org/040gcmg81","country_code":"US","type":"government","lineage":["https://openalex.org/I1299022934","https://openalex.org/I1299303238","https://openalex.org/I4210140884"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Laura Kuhlmann","raw_affiliation_strings":["Division of Cancer Treatment and Diagnosis, National Cancer Institute, NIH, 31 Center Drive, Bldg. 31 Room 3A-44, Bethesda, 20892, MD, USA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Division of Cancer Treatment and Diagnosis, National Cancer Institute, NIH, 31 Center Drive, Bldg. 31 Room 3A-44, Bethesda, 20892, MD, USA","institution_ids":["https://openalex.org/I1299303238","https://openalex.org/I4210140884"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5022641514","display_name":"Sarah Miller","orcid":"https://orcid.org/0000-0003-4251-8126","observed_orcids":["https://orcid.org/0000-0003-4251-8126","https://orcid.org/0000-0002-5133-4911"]},"institutions":[{"id":"https://openalex.org/I1299303238","display_name":"National Institutes of Health","ror":"https://ror.org/01cwqze88","country_code":"US","type":"government","lineage":["https://openalex.org/I1299022934","https://openalex.org/I1299303238"]},{"id":"https://openalex.org/I4210140884","display_name":"National Cancer Institute","ror":"https://ror.org/040gcmg81","country_code":"US","type":"government","lineage":["https://openalex.org/I1299022934","https://openalex.org/I1299303238","https://openalex.org/I4210140884"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Sarah B. Miller","raw_affiliation_strings":["Division of Cancer Treatment and Diagnosis, National Cancer Institute, NIH, 31 Center Drive, Bldg. 31 Room 3A-44, Bethesda, 20892, MD, USA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Division of Cancer Treatment and Diagnosis, National Cancer Institute, NIH, 31 Center Drive, Bldg. 31 Room 3A-44, Bethesda, 20892, MD, USA","institution_ids":["https://openalex.org/I1299303238","https://openalex.org/I4210140884"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5075327419","display_name":"Lamin Juwara","orcid":"https://orcid.org/0000-0001-9934-6623","observed_orcids":["https://orcid.org/0000-0001-9934-6623"]},"institutions":[{"id":"https://openalex.org/I4210130649","display_name":"Frederick National Laboratory for Cancer Research","ror":"https://ror.org/03v6m3209","country_code":"US","type":"facility","lineage":["https://openalex.org/I1299022934","https://openalex.org/I1299303238","https://openalex.org/I4210130649","https://openalex.org/I4210140884"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Lamin Juwara","raw_affiliation_strings":["Clinical Monitoring Research Program, Clinical Research Directorate, Frederick National Laboratory for Cancer Research, Frederick, MD, USA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Clinical Monitoring Research Program, Clinical Research Directorate, Frederick National Laboratory for Cancer Research, Frederick, MD, USA","institution_ids":["https://openalex.org/I4210130649"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5026863845","display_name":"Jerry M. Collins","orcid":"https://orcid.org/0009-0008-7186-4101","observed_orcids":["https://orcid.org/0009-0008-7186-4101"]},"institutions":[{"id":"https://openalex.org/I4210140884","display_name":"National Cancer Institute","ror":"https://ror.org/040gcmg81","country_code":"US","type":"government","lineage":["https://openalex.org/I1299022934","https://openalex.org/I1299303238","https://openalex.org/I4210140884"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Jerry Collins","raw_affiliation_strings":["Developmental Therapeutics Program, Division of Cancer Treatment and Diagnosis, National Cancer Institute, Bethesda, MD, USA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Developmental Therapeutics Program, Division of Cancer Treatment and Diagnosis, National Cancer Institute, Bethesda, MD, USA","institution_ids":["https://openalex.org/I4210140884"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5090468019","display_name":"Robert J. Kinders","orcid":"https://orcid.org/0000-0002-5310-3367","observed_orcids":["https://orcid.org/0000-0002-5310-3367"]},"institutions":[{"id":"https://openalex.org/I4210130649","display_name":"Frederick National Laboratory for Cancer Research","ror":"https://ror.org/03v6m3209","country_code":"US","type":"facility","lineage":["https://openalex.org/I1299022934","https://openalex.org/I1299303238","https://openalex.org/I4210130649","https://openalex.org/I4210140884"]},{"id":"https://openalex.org/I4396570585","display_name":"Leidos Biomedical Research Inc. (United States)","ror":"https://ror.org/00bardy64","country_code":"US","type":"company","lineage":["https://openalex.org/I114662689","https://openalex.org/I4396570585"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Robert J. Kinders","raw_affiliation_strings":["Clinical Pharmacodynamic Biomarkers Program, Applied/Developmental Research Directorate, Frederick National Laboratory for Cancer Research, Frederick, MD, USA","Leidos Biomedical Research, Frederick National Laboratory for Cancer Research, Frederick, MD, 21702, USA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Clinical Pharmacodynamic Biomarkers Program, Applied/Developmental Research Directorate, Frederick National Laboratory for Cancer Research, Frederick, MD, USA","institution_ids":["https://openalex.org/I4210130649"]},{"raw_affiliation_string":"Leidos Biomedical Research, Frederick National Laboratory for Cancer Research, Frederick, MD, 21702, USA","institution_ids":["https://openalex.org/I4210130649","https://openalex.org/I4396570585"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5057382599","display_name":"Ralph E. Parchment","orcid":"https://orcid.org/0009-0002-2634-7195","observed_orcids":["https://orcid.org/0009-0002-2634-7195"]},"institutions":[{"id":"https://openalex.org/I4210130649","display_name":"Frederick National Laboratory for Cancer Research","ror":"https://ror.org/03v6m3209","country_code":"US","type":"facility","lineage":["https://openalex.org/I1299022934","https://openalex.org/I1299303238","https://openalex.org/I4210130649","https://openalex.org/I4210140884"]},{"id":"https://openalex.org/I4396570585","display_name":"Leidos Biomedical Research Inc. (United States)","ror":"https://ror.org/00bardy64","country_code":"US","type":"company","lineage":["https://openalex.org/I114662689","https://openalex.org/I4396570585"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Ralph E. Parchment","raw_affiliation_strings":["Clinical Pharmacodynamic Biomarkers Program, Applied/Developmental Research Directorate, Frederick National Laboratory for Cancer Research, Frederick, MD, USA","Leidos Biomedical Research, Frederick National Laboratory for Cancer Research, Frederick, MD, 21702, USA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Clinical Pharmacodynamic Biomarkers Program, Applied/Developmental Research Directorate, Frederick National Laboratory for Cancer Research, Frederick, MD, USA","institution_ids":["https://openalex.org/I4210130649"]},{"raw_affiliation_string":"Leidos Biomedical Research, Frederick National Laboratory for Cancer Research, Frederick, MD, 21702, USA","institution_ids":["https://openalex.org/I4210130649","https://openalex.org/I4396570585"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5160967458","display_name":"Alice P. Chen","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I1299303238","display_name":"National Institutes of Health","ror":"https://ror.org/01cwqze88","country_code":"US","type":"government","lineage":["https://openalex.org/I1299022934","https://openalex.org/I1299303238"]},{"id":"https://openalex.org/I4210140884","display_name":"National Cancer Institute","ror":"https://ror.org/040gcmg81","country_code":"US","type":"government","lineage":["https://openalex.org/I1299022934","https://openalex.org/I1299303238","https://openalex.org/I4210140884"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Alice P. Chen","raw_affiliation_strings":["Division of Cancer Treatment and Diagnosis, National Cancer Institute, NIH, 31 Center Drive, Bldg. 31 Room 3A-44, Bethesda, 20892, MD, USA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Division of Cancer Treatment and Diagnosis, National Cancer Institute, NIH, 31 Center Drive, Bldg. 31 Room 3A-44, Bethesda, 20892, MD, USA","institution_ids":["https://openalex.org/I1299303238","https://openalex.org/I4210140884"]}]},{"author_position":"last","author":{"id":"https://openalex.org/A5041200743","display_name":"James H. Doroshow","orcid":"https://orcid.org/0000-0002-4463-1790","observed_orcids":["https://orcid.org/0000-0002-4463-1790"]},"institutions":[{"id":"https://openalex.org/I1299303238","display_name":"National Institutes of Health","ror":"https://ror.org/01cwqze88","country_code":"US","type":"government","lineage":["https://openalex.org/I1299022934","https://openalex.org/I1299303238"]},{"id":"https://openalex.org/I4210140884","display_name":"National Cancer Institute","ror":"https://ror.org/040gcmg81","country_code":"US","type":"government","lineage":["https://openalex.org/I1299022934","https://openalex.org/I1299303238","https://openalex.org/I4210140884"]},{"id":"https://openalex.org/I4210149717","display_name":"Center for Cancer Research","ror":"https://ror.org/05bjen692","country_code":"US","type":"facility","lineage":["https://openalex.org/I1299022934","https://openalex.org/I1299303238","https://openalex.org/I4210140884","https://openalex.org/I4210149717"]}],"countries":["US"],"is_corresponding":true,"raw_author_name":"James H. Doroshow","raw_affiliation_strings":["Center for Cancer Research, National Cancer Institute, Bethesda, MD, USA. doroshoj@mail.nih.gov","Division of Cancer Treatment and Diagnosis, National Cancer Institute, NIH, 31 Center Drive, Bldg. 31 Room 3A-44, Bethesda, 20892, MD, USA. doroshoj@mail.nih.gov"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Center for Cancer Research, National Cancer Institute, Bethesda, MD, USA. doroshoj@mail.nih.gov","institution_ids":["https://openalex.org/I1299303238","https://openalex.org/I4210140884","https://openalex.org/I4210149717"]},{"raw_affiliation_string":"Division of Cancer Treatment and Diagnosis, National Cancer Institute, NIH, 31 Center Drive, Bldg. 31 Room 3A-44, Bethesda, 20892, MD, USA. doroshoj@mail.nih.gov","institution_ids":["https://openalex.org/I4210140884"]}]}],"institutions":[],"countries_distinct_count":1,"institutions_distinct_count":7,"corresponding_author_ids":["https://openalex.org/A5041200743"],"corresponding_institution_ids":["https://openalex.org/I1299303238","https://openalex.org/I4210140884","https://openalex.org/I4210149717"],"apc_list":{"value":4390,"currency":"USD","value_usd":4390},"apc_paid":{"value":4390,"currency":"USD","value_usd":4390},"fwci":0.0,"has_fulltext":true,"cited_by_count":0,"citation_normalized_percentile":{"value":0.0,"is_in_top_1_percent":false,"is_in_top_10_percent":false},"cited_by_percentile_year":null,"biblio":{"volume":"96","issue":"1","first_page":null,"last_page":null},"is_retracted":false,"is_paratext":false,"is_xpac":false,"primary_topic":{"id":"https://openalex.org/T10269","display_name":"Epigenetics and DNA Methylation","score":0.9599999785423279,"subfield":{"id":"https://openalex.org/subfields/1312","display_name":"Molecular Biology"},"field":{"id":"https://openalex.org/fields/13","display_name":"Biochemistry, Genetics and Molecular Biology"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}},"topics":[{"id":"https://openalex.org/T10269","display_name":"Epigenetics and DNA Methylation","score":0.9599999785423279,"subfield":{"id":"https://openalex.org/subfields/1312","display_name":"Molecular Biology"},"field":{"id":"https://openalex.org/fields/13","display_name":"Biochemistry, Genetics and Molecular Biology"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}},{"id":"https://openalex.org/T11845","display_name":"Cancer therapeutics and mechanisms","score":0.007000000216066837,"subfield":{"id":"https://openalex.org/subfields/1312","display_name":"Molecular Biology"},"field":{"id":"https://openalex.org/fields/13","display_name":"Biochemistry, Genetics and Molecular Biology"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}},{"id":"https://openalex.org/T10129","display_name":"Glioma Diagnosis and Treatment","score":0.006599999964237213,"subfield":{"id":"https://openalex.org/subfields/2730","display_name":"Oncology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}}],"keywords":[{"id":"https://openalex.org/keywords/dnmt-inhibitors","display_name":"DNMT inhibitors","score":0.7110000252723694},{"id":"https://openalex.org/keywords/cytidine-analogs","display_name":"cytidine analogs","score":0.8379999995231628},{"id":"https://openalex.org/keywords/solid-tumors","display_name":"solid tumors","score":0.949999988079071},{"id":"https://openalex.org/keywords/circulating-tumor-cells","display_name":"circulating tumor cells","score":0.996999979019165},{"id":"https://openalex.org/keywords/epigenetic-modulation","display_name":"epigenetic modulation","score":0.8500000238418579},{"id":"https://openalex.org/keywords/pharmacokinetics","display_name":"pharmacokinetics","score":0.8069999814033508},{"id":"https://openalex.org/keywords/dose-limiting-toxicity","display_name":"dose-limiting toxicity","score":0.8050000071525574},{"id":"https://openalex.org/keywords/maximum-tolerated-dose","display_name":"maximum tolerated dose","score":0.7459999918937683},{"id":"https://openalex.org/keywords/oral-anticancer-drugs","display_name":"oral anticancer drugs","score":0.49300000071525574}],"concepts":[{"id":"https://openalex.org/C112705442","wikidata":"https://www.wikidata.org/wiki/Q323936","display_name":"Pharmacokinetics","level":2,"score":0.7480999827384949},{"id":"https://openalex.org/C71924100","wikidata":"https://www.wikidata.org/wiki/Q11190","display_name":"Medicine","level":0,"score":0.7168999910354614},{"id":"https://openalex.org/C111113717","wikidata":"https://www.wikidata.org/wiki/Q725307","display_name":"Pharmacodynamics","level":3,"score":0.6812000274658203},{"id":"https://openalex.org/C2781184954","wikidata":"https://www.wikidata.org/wiki/Q422538","display_name":"Cytidine","level":3,"score":0.6363999843597412},{"id":"https://openalex.org/C197934379","wikidata":"https://www.wikidata.org/wiki/Q2047938","display_name":"Adverse effect","level":2,"score":0.6035000085830688},{"id":"https://openalex.org/C126322002","wikidata":"https://www.wikidata.org/wiki/Q11180","display_name":"Internal medicine","level":1,"score":0.461899995803833},{"id":"https://openalex.org/C61511704","wikidata":"https://www.wikidata.org/wiki/Q1671857","display_name":"Incidence (geometry)","level":2,"score":0.4447000026702881},{"id":"https://openalex.org/C2777334693","wikidata":"https://www.wikidata.org/wiki/Q659446","display_name":"Maximum tolerated dose","level":3,"score":0.4438999891281128},{"id":"https://openalex.org/C98274493","wikidata":"https://www.wikidata.org/wiki/Q128406","display_name":"Pharmacology","level":1,"score":0.4088999927043915},{"id":"https://openalex.org/C2779984678","wikidata":"https://www.wikidata.org/wiki/Q2145898","display_name":"Response Evaluation Criteria in Solid Tumors","level":4,"score":0.39739999175071716},{"id":"https://openalex.org/C143998085","wikidata":"https://www.wikidata.org/wiki/Q162555","display_name":"Oncology","level":1,"score":0.3682999908924103},{"id":"https://openalex.org/C2776694085","wikidata":"https://www.wikidata.org/wiki/Q974135","display_name":"Chemotherapy","level":2,"score":0.3434000015258789},{"id":"https://openalex.org/C79410662","wikidata":"https://www.wikidata.org/wiki/Q1251001","display_name":"Dose\u2013response relationship","level":2,"score":0.33660000562667847},{"id":"https://openalex.org/C19831878","wikidata":"https://www.wikidata.org/wiki/Q659446","display_name":"Therapeutic index","level":3,"score":0.3028999865055084},{"id":"https://openalex.org/C2778822529","wikidata":"https://www.wikidata.org/wiki/Q1951525","display_name":"Progressive disease","level":3,"score":0.2883000075817108},{"id":"https://openalex.org/C90924648","wikidata":"https://www.wikidata.org/wiki/Q120569","display_name":"Gastroenterology","level":1,"score":0.2865000069141388},{"id":"https://openalex.org/C31760486","wikidata":"https://www.wikidata.org/wiki/Q7180990","display_name":"Phases of clinical research","level":3,"score":0.2809999883174896},{"id":"https://openalex.org/C2993640289","wikidata":"https://www.wikidata.org/wiki/Q1216998","display_name":"Solid tumor","level":3,"score":0.26820001006126404},{"id":"https://openalex.org/C2776239401","wikidata":"https://www.wikidata.org/wiki/Q416451","display_name":"Azacitidine","level":5,"score":0.2644999921321869},{"id":"https://openalex.org/C2778397455","wikidata":"https://www.wikidata.org/wiki/Q50429865","display_name":"Antimetabolite","level":3,"score":0.26420000195503235},{"id":"https://openalex.org/C61238886","wikidata":"https://www.wikidata.org/wiki/Q5121689","display_name":"Circulating tumor cell","level":4,"score":0.25760000944137573},{"id":"https://openalex.org/C2779134260","wikidata":"https://www.wikidata.org/wiki/Q12136","display_name":"Disease","level":2,"score":0.2533999979496002}],"mesh":[{"descriptor_ui":"D000328","descriptor_name":"Adult","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D000368","descriptor_name":"Aged","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D000970","descriptor_name":"Antineoplastic Agents","qualifier_ui":"Q000008","qualifier_name":"administration & dosage","is_major_topic":true},{"descriptor_ui":"D003841","descriptor_name":"Deoxycytidine","qualifier_ui":"Q000008","qualifier_name":"administration & dosage","is_major_topic":true},{"descriptor_ui":"D003841","descriptor_name":"Deoxycytidine","qualifier_ui":"Q000031","qualifier_name":"analogs & derivatives","is_major_topic":true},{"descriptor_ui":"D004305","descriptor_name":"Dose-Response Relationship, Drug","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D005260","descriptor_name":"Female","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D006801","descriptor_name":"Humans","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D008297","descriptor_name":"Male","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D008875","descriptor_name":"Middle Aged","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D009360","descriptor_name":"Neoplastic Cells, Circulating","qualifier_ui":"Q000187","qualifier_name":"drug effects","is_major_topic":false},{"descriptor_ui":"D009369","descriptor_name":"Neoplasms","qualifier_ui":"Q000188","qualifier_name":"drug therapy","is_major_topic":true},{"descriptor_ui":"D009369","descriptor_name":"Neoplasms","qualifier_ui":"Q000235","qualifier_name":"genetics","is_major_topic":true},{"descriptor_ui":"D009369","descriptor_name":"Neoplasms","qualifier_ui":"Q000473","qualifier_name":"pathology","is_major_topic":true},{"descriptor_ui":"D013872","descriptor_name":"Thionucleosides","qualifier_ui":"Q000008","qualifier_name":"administration & dosage","is_major_topic":true},{"descriptor_ui":"D019941","descriptor_name":"Cyclin-Dependent Kinase Inhibitor p16","qualifier_ui":"Q000235","qualifier_name":"genetics","is_major_topic":false},{"descriptor_ui":"D020714","descriptor_name":"Maximum Tolerated Dose","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false}],"locations_count":3,"locations":[{"id":"doi:10.1007/s00280-026-04969-8","doi":"https://doi.org/10.1007/s00280-026-04969-8","is_oa":true,"landing_page_url":"https://doi.org/10.1007/s00280-026-04969-8","pdf_url":"https://link.springer.com/content/pdf/10.1007/s00280-026-04969-8.pdf","source":{"id":"https://openalex.org/S117498271","display_name":"Cancer Chemotherapy and Pharmacology","issn_l":"0344-5704","issn":["0344-5704","1432-0843"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["cwts-core","dongbi-b","doyens","jufo-1","ki-jl-1","medline","norway-1","poland-100","russia-white-list-1"],"host_organization":"https://openalex.org/P4310319900","host_organization_name":"Springer Science+Business Media","host_organization_lineage":["https://openalex.org/P4310319900","https://openalex.org/P4310319965"],"host_organization_lineage_names":["Springer Science+Business Media","Springer Nature"],"type":"journal"},"license":"cc-by","license_id":"https://openalex.org/licenses/cc-by","version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Cancer Chemotherapy and Pharmacology","raw_type":"journal-article"},{"id":"pmh:oai:pubmedcentral.nih.gov:13739968","doi":null,"is_oa":true,"landing_page_url":"https://pmc.ncbi.nlm.nih.gov/articles/PMC13739968/","pdf_url":"https://pmc.ncbi.nlm.nih.gov/articles/PMC13739968/pdf/280_2026_Article_4969.pdf","source":{"id":"https://openalex.org/S2764455111","display_name":"PubMed Central","issn_l":null,"issn":null,"is_oa":true,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":"https://openalex.org/I1299303238","host_organization_name":"National Institutes of Health","host_organization_lineage":["https://openalex.org/I1299303238"],"host_organization_lineage_names":[],"type":"repository"},"license":"cc-by","license_id":"https://openalex.org/licenses/cc-by","version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Cancer Chemother Pharmacol","raw_type":"Text"},{"id":"pmid:42986444","doi":null,"is_oa":false,"landing_page_url":"https://pubmed.ncbi.nlm.nih.gov/42986444","pdf_url":null,"source":{"id":"https://openalex.org/S4306525036","display_name":"PubMed","issn_l":null,"issn":null,"is_oa":false,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":"https://openalex.org/I1299303238","host_organization_name":"National Institutes of Health","host_organization_lineage":["https://openalex.org/I1299303238"],"host_organization_lineage_names":[],"type":"repository"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Cancer chemotherapy and pharmacology","raw_type":"Journal Article"}],"best_oa_location":{"id":"doi:10.1007/s00280-026-04969-8","doi":"https://doi.org/10.1007/s00280-026-04969-8","is_oa":true,"landing_page_url":"https://doi.org/10.1007/s00280-026-04969-8","pdf_url":"https://link.springer.com/content/pdf/10.1007/s00280-026-04969-8.pdf","source":{"id":"https://openalex.org/S117498271","display_name":"Cancer Chemotherapy and Pharmacology","issn_l":"0344-5704","issn":["0344-5704","1432-0843"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["cwts-core","dongbi-b","doyens","jufo-1","ki-jl-1","medline","norway-1","poland-100","russia-white-list-1"],"host_organization":"https://openalex.org/P4310319900","host_organization_name":"Springer Science+Business Media","host_organization_lineage":["https://openalex.org/P4310319900","https://openalex.org/P4310319965"],"host_organization_lineage_names":["Springer Science+Business Media","Springer Nature"],"type":"journal"},"license":"cc-by","license_id":"https://openalex.org/licenses/cc-by","version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Cancer Chemotherapy and Pharmacology","raw_type":"journal-article"},"sustainable_development_goals":[{"display_name":"Good health and well-being","id":"https://metadata.un.org/sdg/3","score":0.9940000176429749}],"study_designs":[{"display_name":"Clinical Trial","id":"https://openalex.org/study-designs/clinical-trial"}],"awards":[{"id":"https://openalex.org/G6012682559","display_name":null,"funder_award_id":"HHSN261201500003I","funder_id":"https://openalex.org/F4320337351","funder_display_name":"National Cancer Institute"},{"id":"https://openalex.org/G6336093431","display_name":null,"funder_award_id":"HHSN261201500003I","funder_id":"https://openalex.org/F4320306085","funder_display_name":"U.S. Department of Health and Human Services"},{"id":"https://openalex.org/G8882569155","display_name":null,"funder_award_id":"HHSN261201500003I","funder_id":"https://openalex.org/F4320332161","funder_display_name":"National Institutes of Health"}],"funders":[{"id":"https://openalex.org/F4320306085","display_name":"U.S. Department of Health and Human Services","ror":"https://ror.org/033jnv181"},{"id":"https://openalex.org/F4320332161","display_name":"National Institutes of Health","ror":"https://ror.org/01cwqze88"},{"id":"https://openalex.org/F4320337351","display_name":"National Cancer Institute","ror":"https://ror.org/040gcmg81"}],"has_content":{"pdf":true,"grobid_xml":true},"content_urls":{"pdf":"https://content.openalex.org/works/W7225319139.pdf","grobid_xml":"https://content.openalex.org/works/W7225319139.grobid-xml"},"referenced_works_count":32,"referenced_works":["https://openalex.org/W1027568982","https://openalex.org/W1658127082","https://openalex.org/W1989113698","https://openalex.org/W1993278112","https://openalex.org/W1993851382","https://openalex.org/W2019607817","https://openalex.org/W2021424812","https://openalex.org/W2030984044","https://openalex.org/W2035147362","https://openalex.org/W2046553666","https://openalex.org/W2101645581","https://openalex.org/W2132005991","https://openalex.org/W2141086589","https://openalex.org/W2148428508","https://openalex.org/W2162600049","https://openalex.org/W2171013411","https://openalex.org/W2346066981","https://openalex.org/W2613870926","https://openalex.org/W2792487615","https://openalex.org/W2808109470","https://openalex.org/W3016741434","https://openalex.org/W3083284516","https://openalex.org/W3092796339","https://openalex.org/W3147465918","https://openalex.org/W3197730637","https://openalex.org/W4282826638","https://openalex.org/W4295517297","https://openalex.org/W4390940948","https://openalex.org/W4407157342","https://openalex.org/W4414367076","https://openalex.org/W4414544949","https://openalex.org/W7116671514"],"related_works":["https://openalex.org/W7116671514","https://openalex.org/W1989113698","https://openalex.org/W2947917754","https://openalex.org/W2991839479","https://openalex.org/W3016741434","https://openalex.org/W3167467515","https://openalex.org/W1964337073","https://openalex.org/W2082056146","https://openalex.org/W2586221063","https://openalex.org/W2889723980"],"abstract_inverted_index":{"PURPOSE:":[0],"The":[1,111,118],"DNA":[2],"methyltransferase":[3],"(DNMT)":[4],"inhibitor":[5],"4'-thio-2'-deoxycytidine":[6],"(TdCyd),":[7],"a":[8,69,96],"second-generation":[9],"cytidine":[10],"analog,":[11],"demonstrated":[12],"potent":[13],"preclinical":[14],"antitumor":[15],"activity":[16,30],"and":[17,28,49,102,135,200,210,220],"favorable":[18],"pharmacokinetics,":[19],"which":[20,169],"led":[21],"us":[22],"to":[23,58,68,232],"explore":[24],"its":[25],"safety,":[26],"efficacy":[27],"anti-tumor":[29],"in":[31,51,76,143,153,168,178,183,205,238,245],"patients":[32,38,108,128,159,170,206],"with":[33,39,126,207],"solid":[34,41],"tumors.":[35],"METHODS:":[36],"Adult":[37],"advanced":[40],"tumors":[42],"received":[43],"TdCyd":[44,99,194,225,244],"orally":[45],"on":[46,129],"days":[47],"1-5":[48],"8-12":[50],"21-day":[52],"cycles.":[53],"Dose":[54],"escalation":[55,74],"proceeded":[56],"according":[57],"design":[59,75],"4":[60],"of":[61,79,92,98,146,156,158,186,188,193,212,243],"the":[62,77,144],"Simon":[63],"accelerated":[64],"titration":[65],"design,":[66],"changing":[67],"3":[70,72,127],"+":[71],"dose":[73,114,166,198,226],"event":[78],"dose-limiting":[80],"toxicities.":[81],"Blood":[82],"samples":[83],"were":[84,109,171,196,203],"collected":[85],"for":[86,103,131,161,173],"circulating":[87],"tumor":[88],"cell":[89],"(CTC)":[90],"evaluation":[91],"p16":[93,162,176,221],"re-expression":[94,177,222],"as":[95],"marker":[97],"epigenetic":[100],"modulation,":[101],"pharmacokinetic":[104],"analysis.":[105],"RESULTS:":[106],"Twenty-seven":[107],"enrolled.":[110],"maximum":[112],"tolerated":[113],"was":[115,121,137,151,181],"not":[116],"reached.":[117],"best":[119],"response":[120,163],"prolonged":[122],"stable":[123],"disease":[124],"(SD),":[125],"treatment":[130],"\u2265":[132],"6":[133],"cycles,":[134],"there":[136],"no":[138],"dose-response":[139],"relationship.":[140],"An":[141],"increase":[142],"proportion":[145],"p16-expressing":[147],"cytokeratin-positive":[148],"(CK+)":[149],"CTCs":[150,180],"detected":[152,204],"71%":[154],"(15":[155],"21)":[157],"evaluable":[160,189],"at":[164,223],"every":[165],"level":[167],"assessable":[172],"pharmacodynamic":[174],"response;":[175],"vimentin-positive":[179],"reported":[182],"38%":[184],"(6":[185],"16)":[187],"patients.":[190],"Plasma":[191],"levels":[192,202,227],"metabolites":[195],"largely":[197],"proportional":[199],"higher":[201,208],"incidence":[209],"severity":[211],"study":[213],"drug-related":[214],"adverse":[215],"events.":[216],"CONCLUSION:":[217],"Prolonged":[218],"SD":[219],"lower":[224],"suggest":[228],"that":[229],"longer":[230],"exposures":[231],"low":[233],"concentrations":[234],"is":[235],"worth":[236],"exploring":[237],"future":[239],"trials,":[240],"including":[241],"studies":[242],"therapeutic":[246],"combinations.":[247]},"counts_by_year":[],"updated_date":"2026-11-11T12:16:26.678958","created_date":"2026-11-06T00:00:00"}